SCHEMBL4590060

SCHEMBL4590060

COc1ccccc1C1(N2CCC[C@H]2C(=O)N(C)C)C(=O)Nc2cc(C)c(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OXTR P30559 8/20 0.43
AVPR1B P47901 8/20 0.43
AVPR1A P37288 7/20 0.43
BRD4 O60885 4/20 0.43
AVPR2 P30518 1/20 0.39
GPR65 Q8IYL9 1/20 0.39
ACHE P22303 2/20 0.39
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
CASP3 P42574 1/20 0.35
KMT2A Q03164 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7162897 1.00 OXTR (0.43) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4589526 0.97 OXTR (0.41) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4590130 0.97 OXTR (0.43) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4590186 0.95 OXTR (0.44) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4590199 0.92 OXTR (0.42) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4590303 0.89 OXTR (0.43) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL2495591 0.89 OXTR (0.50) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL6945529 0.88 POLB (0.40) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4588934 0.87 OXTR (0.39) OXTRAVPR1BAVPR1ABRD4AVPR2
SCHEMBL4588875 0.87 BRD4 (0.42) OXTRAVPR1BAVPR1ABRD4AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425566-B2 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2008-09-16 US disclosed
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2005-08-11 US disclosed
US-6864277-B2 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2005-03-08 US disclosed
EP-1296976-B1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI AVENTIS (FR) 2005-01-26 EP disclosed
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin SANOFI-AVENTIS (FR) 2003-08-28 US disclosed
EP-1296976-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Sanofi-Aventis (FR) 2003-04-02 EP disclosed
WO-2001098295-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-SYNTHELABO (FR) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin AVPR1B, AVPR1A, AVPR2 OXTR 12/4885AVPR1B 1/4885AVPR1A 2/4885
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them AVPR1B, AVPR2, AVPR1A OXTR 9/4885AVPR1B 1/4885AVPR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.